menu
    • menu

    Company profile for Siren Biotechnology

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Siren Biotechnology combines two transformative therapeutic technologies – AAV gene therapy and cytokine immunotherapy - into a single, reimagined modality that overcomes key challenges and redefines how we destroy tumor cells and elicit anti-tumor immunity. At Siren, we’ve got one: Universal AAV Immuno-Gene Therapy.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Siren BiotechnologyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    San Francisco, California 94158
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://sirenbiotechnology.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/siren-biotechnology-inc
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Siren Bio Highlights Clinical Progress At 2026 Health Conferences
    Siren Bio Highlights Clinical Progress At 2026 Health Conferences

    07 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214573/0/en/Siren-Biotechnology-to-Showcase-Clinical-Stage-Momentum-at-Major-2026-Healthcare-Conferences.html

    GLOBENEWSWIRE
    07 Jan 2026
    Share Share
    Siren Biotechnology to Present AAV Immuno-Gene Therapy Data
    Siren Biotechnology to Present AAV Immuno-Gene Therapy Data

    12 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/12/3079483/0/en/Siren-Biotechnology-to-Present-Universal-AAV-Immuno-Gene-Therapy-Data-at-the-2025-American-Society-of-Gene-and-Cell-Therapy-ASGCT-Annual-Meeting.html

    GLOBENEWSWIRE
    12 May 2025
    Share Share
    Siren Biotechnology Expands Advisory Board with Industry Leaders
    Siren Biotechnology Expands Advisory Board with Industry Leaders

    05 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/05/3037647/0/en/Siren-Biotechnology-Expands-Clinical-and-Scientific-Advisory-Board-with-Key-Industry-Leaders.html

    GLOBENEWSWIRE
    05 Mar 2025
    Share Share
    Siren Biotech Reveals SRN-101 as Lead for High-Grade Gliomas
    Siren Biotech Reveals SRN-101 as Lead for High-Grade Gliomas

    18 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/18/2982962/0/en/Siren-Biotechnology-Reveals-SRN-101-as-Lead-Asset-for-High-Grade-Gliomas-with-Both-Orphan-Drug-and-Rare-Pediatric-Disease-Designations-from-the-FDA.html

    GLOBENEWSWIRE
    18 Nov 2024
    Share Share
    Merck Names Siren Biotech As North American Advance Biotech
    Merck Names Siren Biotech As North American Advance Biotech

    04 Jun 2024

    // PRESS RELEASE

    https://www.sigmaaldrich.com/IN/en/collections/press/siren-biotechnology-winner-advance-biotech-grant-program

    PRESS RELEASE
    04 Jun 2024
    Share Share
    MilliporeSigma: Siren Bio Wins N.America Advance Biotech Grant
    MilliporeSigma: Siren Bio Wins N.America Advance Biotech Grant

    04 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240604753636/en

    BUSINESSWIRE
    04 Jun 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search